
    
      -  A traditional 3+3 dose escalation scheme will be used to identify the recommended phase
           2 dose (RP2D) of crizotinib when used in combination with standard fixed dose
           enzalutamide.

        -  Patients who fulfill eligibility criteria will be entered into the trial to receive
           crizotinib and enzalutamide.

        -  After the screening procedures confirm participation in the research study:

             -  The participant will be given a study drug-dosing calendar for each treatment
                cycle. The investigators are looking for the highest dose of the combination of
                study drugs that can be administered safely without severe or unmanageable side
                effects in participants that have, not everyone who participates in this research
                study will receive the same dose of the study drug. The dose given will depend on
                the number of participants who have been enrolled in the study prior and how well
                the dose was tolerated.
    
  